Consider treatment response and tolerability when selecting the maintenance dosage
The upper arm The back of the upper arm is the third approved location
Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Diarrhea or Constipation: Changes in bowel habits are common, with constipation reported slightly more often with semaglutide
Eating smaller, more frequent meals, avoiding fatty or greasy foods, and taking your injection at the best time for your schedule can help manage nausea
Dangers: The U.S